Company profile for Precision NeuroMed

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Precision NeuroMed is developing the PNM platform, an innovative drug delivery system designed to transform the treatment of central nervous system (CNS) diseases. The blood-brain barrier (BBB), while protecting the brain, also blocks most drugs—allowing less than 0.1% of small molecules and 0.006% of protein-based drugs to enter brain tissue. The PNM platform overcomes this challenge by enabling targeted delivery of nanopar...
Precision NeuroMed is developing the PNM platform, an innovative drug delivery system designed to transform the treatment of central nervous system (CNS) diseases. The blood-brain barrier (BBB), while protecting the brain, also blocks most drugs—allowing less than 0.1% of small molecules and 0.006% of protein-based drugs to enter brain tissue. The PNM platform overcomes this challenge by enabling targeted delivery of nanoparticles, including small molecules, proteins, liposomes, and AAVs, directly to the brain at therapeutic concentrations, offering new possibilities for effective CNS therapies.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3200 Bridge Pkwy, Redwood City, California 94065, US
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

IPhEB Russia

Not Confirmed

envelop Contact Supplier

IPhEB Russia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.contractpharma.com/breaking-news/brainlab-precision-neuromed-partner-on-ai-enabled-drug-delivery-to-brain/

CONTRACTPHARMA
25 Feb 2026

https://www.prnewswire.com/news-releases/precision-neuromed-granted-fda-orphan-drug-designation-by-us-fda-for-treatment-of-glioblastoma-multiforme-gbm-302575427.html

PR NEWSWIRE
07 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty